A Double-blind, Placebo-controlled Study in Healthy Volunteers to Determine the Safety and Tolerability of Single, Ascending Subcutaneous Doses of Sevuparin
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Sevuparin (Primary)
- Indications Falciparum malaria; Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Modus Therapeutics
- 15 Jul 2019 Status changed from recruiting to completed.
- 25 Nov 2018 New trial record
- 07 Nov 2018 According to a Modus Therapeutics media release, the company announces that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate this trial.